Skip to main content

November/December 2013, Vol 6, No 9

Insurance Companies’ Perspectives on the Orphan Drug Pipeline

Robert Handfield, PhD, Josh Feldstein, BA

Stakeholder Perspective

Breakthrough Therapy, or Breakthrough Pricing?

by Atheer A. Kaddis, PharmD

Industry Trends

“Project IMPACT: Diabetes” Care Model Improves Health Outcomes in Underserved Populations in 25 Communities with a High Incidence of Diabetes

Benjamin M. Bluml, RPh

Industry Trends

Cost and Drug Utilization Patterns Associated with the Management of Rosacea

Caroline Helwick

Industry Trends

Rehospitalization Is Driving Costs in Pulmonary Arterial Hypertension

Pharmacy Staff Opinions Regarding Diabetic Retinopathy Screenings in the Community Setting: Findings from a Brief Survey

Miranda G. Law, BS, PharmD Candidate, Stephanie Komura, BS, PharmD Candidate, Ann P. Murchison, MD, MPH, Laura T. Pizzi, PharmD, MPH

Stakeholder Perspective

Screening for Diabetic Retinopathy in the Community Setting: Exploring the Options

by Gary M. Owens, MD

Modeling the Frequency and Costs Associated with Postsurgical Gastrointestinal Adverse Events for Tapentadol IR versus Oxycodone IR

Andrew Paris, MBA, Chris M. Kozma, PhD, Wing Chow, PharmD, MPH, Anisha M. Patel, MS, Samir H. Mody, PharmD, MBA, Myoung S. Kim, PhD, MBA

Stakeholder Perspective

Can Substituting Generic Drugs with Brand-Name Agents for Acute Pain Postsurgery Help to Deliver Cost-Effective, Quality Care?

by Matthew Mitchell, PharmD, MBA, FAMCP

Practicing Population Health

David B. Nash, MD, MBA

Editorial, Perspectives

The Affordable Care Act Conundrum: Facing Reality in America’s Giant Social Experiment

Kip Piper, MA, FACHE

Results 1 - 8 of 8